Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

12.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.5K
Amyloid Fibrils03:03

Amyloid Fibrils

6.9K
6.9K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.8K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.8K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gallic acid is a dual α/β-secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer mice.

The Journal of biological chemistry·2020
Same author

Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice.

The Journal of biological chemistry·2018
Same author

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.

Journal of Alzheimer's disease : JAD·2018
Same author

Let's make microglia great again in neurodegenerative disorders.

Journal of neural transmission (Vienna, Austria : 1996)·2017
Same author

Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease.

The Journal of biological chemistry·2017
Same author

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease.

Journal of visualized experiments : JoVE·2017
Same journal

Targeting cholesterol esterification sensitizes liver cancer to CD8<sup>+</sup> T cell attack by impairing metabolic and redox resilience.

Immunity·2026
Same journal

Brain endothelial cells orchestrate a neuroprotective antiviral state in the CNS in response to peripheral viral pattern sensing.

Immunity·2026
Same journal

Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors.

Immunity·2026
Same journal

B cell-derived type I interferon sustains T cell functionality upon strong TCR stimulation during chronic infection.

Immunity·2026
Same journal

Lactate binds and inhibits the innate immune sensor STING to promote tumor immune evasion.

Immunity·2026
Same journal

Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling.

Immunity·2026
See all related articles

Related Experiment Video

Updated: Mar 13, 2026

Rapid Generation of Amyloid from Native Proteins In vitro
05:48

Rapid Generation of Amyloid from Native Proteins In vitro

Published on: December 5, 2013

6.6K

Amyloid Cascade into Clarity.

Tara M Weitz1, Terrence Town1

  • 1Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, 1501 San Pablo Street, Room 321, Los Angeles, CA 90089-2821, USA.

Immunity
|October 21, 2016
PubMed
Summary
This summary is machine-generated.

Aducanumab, a monoclonal antibody, shows promise in a phase 1b trial for Alzheimer's disease. This treatment targets amyloid-β peptides, potentially revitalizing the amyloid cascade hypothesis.

More Related Videos

Fabrication of Amyloid-&#946;-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.8K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.7K

Related Experiment Videos

Last Updated: Mar 13, 2026

Rapid Generation of Amyloid from Native Proteins In vitro
05:48

Rapid Generation of Amyloid from Native Proteins In vitro

Published on: December 5, 2013

6.6K
Fabrication of Amyloid-&#946;-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.8K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.7K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Alzheimer's disease is characterized by amyloid-β peptide aggregation.
  • The amyloid cascade hypothesis posits that amyloid-β is central to disease pathogenesis.
  • Mononuclear phagocytes play a role in neuroinflammation and amyloid clearance.

Purpose of the Study:

  • To evaluate the safety and tolerability of aducanumab in patients with early Alzheimer's disease.
  • To assess the effect of aducanumab on amyloid-β plaque burden.
  • To explore the impact of aducanumab on cognitive decline.

Main Methods:

  • Phase 1b clinical trial design.
  • Administration of aducanumab (monoclonal antibody) at varying doses.
  • Positron emission tomography (PET) imaging to measure amyloid-β load.
  • Cognitive assessments to evaluate clinical outcomes.

Main Results:

  • Aducanumab demonstrated dose- and time-dependent reduction of amyloid-β plaques.
  • The reduction in amyloid-β was associated with clinical benefits in some patient groups.
  • The drug was generally well-tolerated, with manageable side effects.

Conclusions:

  • Aducanumab's ability to reduce amyloid-β plaques supports the amyloid cascade hypothesis.
  • These findings warrant further investigation in larger clinical trials.
  • Targeting amyloid-β with monoclonal antibodies represents a potential therapeutic strategy for Alzheimer's disease.